BioMarin Pharmaceuticals shares are trading lower after Truist Securities lowered its price target on the stock from $140 to $118.
Portfolio Pulse from Benzinga Newsdesk
BioMarin Pharmaceuticals shares declined after Truist Securities reduced its price target from $140 to $118.
September 05, 2024 | 6:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioMarin Pharmaceuticals shares are trading lower following a price target reduction by Truist Securities from $140 to $118.
The reduction in price target by Truist Securities is likely to negatively impact investor sentiment, leading to a short-term decline in BioMarin's stock price. Price target changes by analysts can influence market perception and trading behavior.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100